Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 100
Avg Vol 392
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 84%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, a...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 81 3 3817 3700
Address:
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan
Latest News on ESALF
No data available.